Key Points
- Jason Adair, a Liquidia insider, sold 693 shares on Dec. 1 at an average price of $32.19 for about $22,308, trimming his stake by 0.39% to 175,868 shares (valued ≈ $5.66M); he also executed larger sales in October–November, including 35,656 shares on Nov. 18.
- Liquidia beat Q3 expectations with EPS of ($0.04) vs. a ($0.45) estimate and revenue of $54.34M (vs. $18.86M expected), a ~1106.7% YoY revenue increase, but the company still reports a negative net margin (176.04%) and negative ROE (296.78%).
- The stock opened at $30.79 (down 3.9%) and trades near its 52‑week high of $32.80 with a market cap of $2.68B, while analysts' consensus is a "Moderate Buy" and the average price target is $38.56.
Liquidia Corporation (NASDAQ:LQDA - Get Free Report) insider Jason Adair sold 693 shares of the stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $32.19, for a total value of $22,307.67. Following the completion of the transaction, the insider directly owned 175,868 shares of the company's stock, valued at $5,661,190.92. This trade represents a 0.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Jason Adair also recently made the following trade(s):
- On Tuesday, November 18th, Jason Adair sold 35,656 shares of Liquidia stock. The shares were sold at an average price of $30.03, for a total value of $1,070,749.68.
- On Monday, October 27th, Jason Adair sold 692 shares of Liquidia stock. The stock was sold at an average price of $22.93, for a total transaction of $15,867.56.
- On Monday, October 13th, Jason Adair sold 3,670 shares of Liquidia stock. The shares were sold at an average price of $23.41, for a total transaction of $85,914.70.
Liquidia Stock Down 3.9%
LQDA stock opened at $30.79 on Wednesday. The firm's 50-day moving average is $25.57 and its two-hundred day moving average is $21.56. The company has a market capitalization of $2.68 billion, a price-to-earnings ratio of -21.38 and a beta of 0.48. Liquidia Corporation has a 52 week low of $10.37 and a 52 week high of $32.80. The company has a current ratio of 2.20, a quick ratio of 1.96 and a debt-to-equity ratio of 6.19.
Liquidia (NASDAQ:LQDA - Get Free Report) last posted its quarterly earnings data on Monday, November 3rd. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.41. Liquidia had a negative net margin of 176.04% and a negative return on equity of 296.78%. The business had revenue of $54.34 million during the quarter, compared to analysts' expectations of $18.86 million. Liquidia's revenue for the quarter was up 1106.7% compared to the same quarter last year. On average, analysts forecast that Liquidia Corporation will post -1.51 earnings per share for the current fiscal year.
Institutional Trading of Liquidia
Several hedge funds and other institutional investors have recently modified their holdings of LQDA. Skandinaviska Enskilda Banken AB publ purchased a new stake in Liquidia in the 3rd quarter worth about $30,000. NewEdge Advisors LLC purchased a new position in Liquidia during the 2nd quarter valued at about $25,000. Quarry LP acquired a new position in shares of Liquidia in the 1st quarter valued at about $79,000. Steward Partners Investment Advisory LLC lifted its position in shares of Liquidia by 24.0% in the second quarter. Steward Partners Investment Advisory LLC now owns 6,200 shares of the company's stock worth $77,000 after purchasing an additional 1,200 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its position in shares of Liquidia by 281.2% in the second quarter. Tower Research Capital LLC TRC now owns 6,679 shares of the company's stock worth $83,000 after purchasing an additional 4,927 shares in the last quarter. Institutional investors and hedge funds own 64.54% of the company's stock.
Analyst Upgrades and Downgrades
A number of analysts have recently commented on the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Liquidia in a research note on Wednesday, October 8th. HC Wainwright lifted their price target on shares of Liquidia from $35.00 to $50.00 and gave the stock a "buy" rating in a research report on Tuesday, November 4th. Jefferies Financial Group reaffirmed a "buy" rating and issued a $45.00 price target on shares of Liquidia in a report on Monday, November 3rd. Wells Fargo & Company started coverage on Liquidia in a research note on Monday, October 20th. They set an "overweight" rating and a $31.00 price objective for the company. Finally, BTIG Research restated a "buy" rating and issued a $49.00 target price on shares of Liquidia in a report on Tuesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $38.56.
Read Our Latest Research Report on LQDA
About Liquidia
(
Get Free Report)
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
